Equillium Inc (EQ)

$0.87

Market is closed - opens 7 PM, 16 Sep 2024

Performance

  • $0.85
    $0.94
    $0.87
    downward going graph

    2.07%

    Downside

    Day's Volatility :9.34%

    Upside

    7.43%

    downward going graph
  • $0.45
    $3.25
    $0.87
    downward going graph

    48.28%

    Downside

    52 Weeks Volatility :86.15%

    Upside

    73.23%

    downward going graph

Returns

PeriodEquillium IncIndex (Russel 2000)
3 Months
22.02%
0.0%
6 Months
-65.88%
0.0%
1 Year
8.79%
0.0%
3 Years
-83.89%
-20.0%

Highlights

Market Capitalization
30.8M
Book Value
$0.63
Earnings Per Share (EPS)
-0.23
Wall Street Target Price
6.75
Profit Margin
-19.51%
Operating Margin TTM
-0.72%
Return On Assets TTM
-11.95%
Return On Equity TTM
-33.67%
Revenue TTM
42.6M
Revenue Per Share TTM
1.21
Quarterly Revenue Growth YOY
51.800000000000004%
Gross Profit TTM
15.8M
EBITDA
-9.6M
Diluted Eps TTM
-0.23
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.5
EPS Estimate Next Year
-1.06
EPS Estimate Current Quarter
-0.15
EPS Estimate Next Quarter
0.24

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Equillium Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 675.86%

Current $0.87
Target $6.75

Technicals Summary

Sell

Neutral

Buy

Equillium Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Equillium Inc
Equillium Inc
8.89%
-65.88%
8.79%
-83.89%
-78.68%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.3%
20.26%
38.56%
78.77%
303.42%
Novo Nordisk A/s
Novo Nordisk A/s
1.92%
1.8%
42.06%
173.92%
453.76%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
0.91%
78.6%
37.4%
41.12%
212.93%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.95%
18.74%
38.91%
157.61%
173.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Equillium Inc
Equillium Inc
NA
NA
NA
-0.5
-0.34
-0.12
NA
0.63
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.86
30.86
1.59
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
46.01
46.01
2.08
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Equillium Inc
Equillium Inc
Buy
$30.8M
-78.68%
NA
-19.51%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$128.4B
303.42%
30.86
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$600.4B
453.76%
46.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.1B
212.93%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$125.3B
173.37%
32.84
-4.74%

Insights on Equillium Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 33.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 173.9% return, outperforming this stock by 257.8%

Institutional Holdings

  • Decheng Capital LLC

    12.55%

  • Vanguard Group Inc

    2.38%

  • Cota Capital Management, LLC

    1.59%

  • Renaissance Technologies Corp

    0.85%

  • Geode Capital Management, LLC

    0.61%

  • ADAR1 Capital Management LLC

    0.40%

Company Information

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.

Organization
Equillium Inc
Employees
45
CEO
Mr. Daniel Mark Bradbury
Industry
Health Technology

Discover More

FAQs